PDCD1 and neoplasm: While the technical limitations of the experiment which led to the pooling of mice with different combination ICI treatments into the same cohort prevent definitive conclusions, these findings provide evidence that anti-PD-1 plus anti-CTLA-4 therapy can enhance T-cell recognition of tumour cells, at least in some animals, evidenced by the increased presence of tumour-reactive T cells in the spleen.